# FDA Inspection 1122803 - Piedmont Reproductive Endocrinology Group, Pa - January 28, 2020

Source: https://www.keypedia.com/records/fda_inspections/piedmont-reproductive-endocrinology-group-pa/cd8e6e32-61ee-40f1-a8bc-a99f524af0a6
Source feed: FDA_Inspections

> FDA Inspection 1122803 for Piedmont Reproductive Endocrinology Group, Pa on January 28, 2020. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1122803
- Company Name: Piedmont Reproductive Endocrinology Group, Pa
- Inspection Date: 2020-01-28
- Classification: No Action Indicated (NAI)
- Project Area: Human Cellular, Tissue, and Gene Therapies
- Product Type: Biologics
- Office Name: Center for Biologics Evaluation and Research

## Related Documents

- [FDA Inspection 1300792 - 2026-01-21](https://www.keypedia.com/records/fda_inspections/piedmont-reproductive-endocrinology-group-pa/20389128-90c1-49f2-a420-f61b3f0997e6)
- [FDA Inspection 1193365 - 2022-12-06](https://www.keypedia.com/records/fda_inspections/piedmont-reproductive-endocrinology-group-pa/69e41309-dade-4b59-8c03-0ac021f37409)
- [FDA Inspection 1193365 - 2022-12-06](https://www.keypedia.com/records/fda_inspections/piedmont-reproductive-endocrinology-group-pa/d19975e4-3dd4-44b2-b1cc-875a0c94f554)
- [FDA Inspection 1193365 - 2022-12-06](https://www.keypedia.com/records/fda_inspections/piedmont-reproductive-endocrinology-group-pa/0a410026-f5a3-48e8-98f5-98570cb530ae)
- [FDA Inspection 1122803 - 2020-01-28](https://www.keypedia.com/records/fda_inspections/piedmont-reproductive-endocrinology-group-pa/39576118-925b-4fc0-9018-4ddbcce425d8)

Company: https://www.keypedia.com/companies/piedmont-reproductive-endocrinology-group-pa/b2ee7cdb-2340-42b8-9f2d-d3e318b64d0b

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d